Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability.

Trial Profile

Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs Fludarabine; Mitoxantrone; Rituximab; Sargramostim
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2012 Actual patient number changed from 16 to 15 as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top